- Main limitation: low number of data variables collected (no details on laboratory parameters or ICU interventions)
- Combination of in-house and commercial PCR assays
- Small sample size of antiviral/ immunomodulatory treatment (unable to draw meaningful conclusions about effectiveness)
- Screening policies/ thresholds for SARS-CoV-2 varied across countries

University of Michigan - Ann Arbor

This is the first multinational, multicenter study on pediatric cases of COVID-19 and provides detailed information about morbidity and hospital care for individuals. The study demonstrates that while COVID-19 generally presents with mild symptoms among children, severe COVID-19 can occur among them, although fatality from the disease is rare (CFR 0.69). Since the study population consisted of individuals with severe COVID-19, the true CFR among children in Europe is likely to be even lower than that found in this study. This study also highlights uncertainties regarding treatment options and their effectiveness. 

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study: Discussion

Götzinger, F., Santiago-Garcia, B., et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child and Adolescent Health. 
DOI:https://doi.org/10.1016/S2352-4642(20)30177-2

Learn Before

Related